Status:
UNKNOWN
Optimal Dosing of Vancomycin in an Adult Population of Hemato-oncology
Lead Sponsor:
Ciusss de L'Est de l'Île de Montréal
Conditions:
Vancomycin
Hematologic Malignancies
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This is a single-center prospective pharmacokinetic study. The principal objective is to collect new data among patients with hematologic cancer to develop a Bayesian population pharmacokinetic model ...
Detailed Description
STUDY DESIGN: Prospective, monocentric, pharmacokinetic study. Adults who have been diagnosed with a hematologic malignancy, are hospitalized at Maisonneuve-Rosemont hospital and received at least 3...
Eligibility Criteria
Inclusion
- Subjects aged 18 and over;
- Subjects diagnosed with a hematologic cancer;
- Subjects hospitalized at Maisonneuve-Rosemont hospital between February 2021 and August 2021;
- Intravenous vancomycin treatment prescribed by a doctor;
- Subjects received at least 3 doses of intravenous vancomycin.
Exclusion
- Non-malignant diagnosis (aplastic anemia and rare metabolic diseases);
- Subjects admitted to a critical care unit;
- End-stage renal disease (GFR \< 15 mL/min/1.73m2);
- Patients undergoing dialysis/renal replacement therapy;
- Acute kidney injury at the moment of the first vancomycin dosage (definition adapted from KDIGO criteria):
- Increase in serum creatinine by ≥ 26.5 umol/L within 48 hours or
- Increase in serum creatinine to ≥ 1.5 times baseline within prior 7 days
- Pregnant women;
- Severely burn patients;
- Inability to give free and informed consent.
Key Trial Info
Start Date :
February 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 31 2021
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04758442
Start Date
February 1 2021
End Date
October 31 2021
Last Update
February 17 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Maisonneuve-Rosemont Hospital
Montreal, Quebec, Canada, H1T 2M4